KYMR Kymera Therapeutics, Inc.
USHealthcareAs of 2026-07-02
Why KYMR matters now
Kymera Therapeutics, Inc. (KYMR) is a US stock in Healthcare. The latest InvestLog snapshot shows $113.51 with -0.60% on the session and $9.34B in market capitalization; recent performance reads 1-month +15.73% and YTD +16.22%.
The latest financial table shown here is Q1 2026, with revenue of $34.4M, net income of $-69.2M, and EPS of $-0.71. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.3%.
InvestLog's latest related AI research is a Form 144 Sale note titled "Atlas Venture Fund X, Lp files Form 144 to sell 480,992 KYMR shares worth $48.0M". The latest indexable market news headline is "Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader" from Globe News Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $108.00; recent insider activity includes Jacobs Bruce N. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.73
P/S
144.54
EV/EBITDA
-24.10
DCF Value
$0.13
FCF Yield
-3.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-697.8%
Net Margin
-612.2%
ROE
-25.0%
ROA
-18.9%
ROIC
-22.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $34.4M | $-69.2M | $-0.71 |
| Q4 2025 | $2.9M | $-87.0M | $-0.98 |
| FY 2025 | $39.2M | $-311.4M | $-3.69 |
| Q3 2025 | $2.8M | $-82.2M | $-0.94 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$112.60
Target (Median)
$108.00
Target Range
$97.00 - $133.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.03
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.